Researchers identify DNA marker that could predict treatment response in myelodysplastic syndromes
DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine. That's the key finding of a new multicenter study involving researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
A weight-loss drug eased knee arthritis pain in two major trials
United Kingdom
-
Brain's 'cleanup' molecule could aid recovery after stroke
United Kingdom
-
Blood proteins that may predict brain and cardiovascular health issues identified
United Kingdom
-
Researchers detect signs of neuronal damage in the earliest stage of Huntington's disease
United Kingdom
-
Patient comfort with AI-driven health care hinges on provider oversight
United Kingdom
-
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
United Kingdom
-
Gas prices dip below $4 but inflation remains stubbornly high
United States
-
Martian Volcanic Discovery Could Be ‘Smoking Gun’ in Search for Life
United Kingdom